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Abstract
Purpose: A meta-analysis of sociodemographic variables and their association with late (>180 days
from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was
conducted in patients with high-risk (clinical stages T2c-T4b or Gleason score 8-10 or prostatespecific antigen level >20) prostate cancer.
Methods and materials: Three NRG trials (RTOG 9202, RTOG 9413, and RTOG 9406) that accrued
from 1992 to 2000 were used. Late toxicities were measured with the Radiation Therapy Oncology
Group Late Radiation Morbidity Scale. After controlling for study, age, Karnofsky Performance
Status, and year of accrual, sociodemographic variables were added to the model for each outcome
variable of interest in a stepwise fashion using the Fine-Gray regression models with an entry criterion of 0.05.
Results: A total of 2432 patients were analyzed of whom most were Caucasian (76%), had a
KPS score of 90 to 100 (92%), and received whole-pelvic RT+HT (67%). Of these patients, 13 %
and 16% experienced late grade ≥2 bowel and bladder toxicities, respectively, and 2% and 3%
experienced late grade ≥3 bowel and bladder toxicities, respectively. Late grade ≥2 clustered
bowel and bladder toxicities were seen in approximately 1% of patients and late grade ≥3
clustered toxicities were seen in 2 patients (<1%). The multivariate analysis showed that
patients who received prostate-only RT+HT had a lower risk of experiencing grade ≥2 bowel
toxicities than those who received whole-pelvic RT+long-term (LT) HT (hazard ratio: 0.36;
95% confidence interval, 0.18-0.73; P = .0046 and hazard ratio: 0.43; 95% confidence
interval, 0.23-0.80; P = .008, respectively). Patients who received whole-pelvic RT had similar
chances of having grade ≥2 bowel or bladder toxicities no matter whether they received LT or
short-term HT.
Conclusions: Patients with high-risk prostate cancer who receive whole-pelvic RT+LT HT are more
likely to have a grade ≥2 bowel toxicity than those who receive prostate-only RT. LT bowel and
bladder toxicities were infrequent. Future studies will need to confirm these findings utilizing current
radiation technology and patient-reported outcomes.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Methods and materials

Prostate cancer is the most common cancer in men
with an estimated 161,360 men diagnosed in 2017.1
Patients with high-risk (clinical stages T2c-T4b, or Gleason
score [GS] 8-10, or prostate-specific antigen [PSA] level
>20 ng/mL) prostate cancer account for approximately
15% of the population with prostate cancer.2 Radiation
therapy (RT) is one of the major treatment options for
patients with high-risk prostate cancer.3 However, radiationassociated side effects such as bladder and bowel toxicities
are commonly reported.4 These radiation-associated toxicities can occur and persist many years after the completion
of the treatment and can have significant negative impact
on patients’ quality of life.4,5 Identifying risk factors for
the toxicities can result in a better understanding of their
development and consequently, help manage these toxicities in a more predictive way.
In this study, we combined toxicity data from 3
contemporary randomized clinical trials and conducted a
meta-analysis to identify potential risk factors for late
bowel and bladder toxicities in patients with high-risk
prostate cancer.

A meta-analysis of data from trials RTOG 9202, 9406,
and 9413 was performed. RTOG 9202 was a phase 3 trial
that examined long-term (LT) total androgen suppression
(TAS) after neoadjuvant hormonal cytoreduction and RT
in locally advanced carcinoma of the prostate. RTOG 9406
was a phase 1/2 dose escalation study using 3-dimensional
conformal RT for adenocarcinoma of the prostate. RTOG
9413 was a phase 3 trial that compared whole-pelvic irradiation followed by a prostate boost to prostate irradiation
only as well as neoadjuvant to adjuvant TAS.

Samples
The 3 x trials used in this analysis enrolled patients who
were diagnosed with prostate cancer and subsequently received RT. Details on the inclusion and exclusion criteria
and treatment were published previously.6-8 RTOG 9202 enrolled patients with locally advanced prostate cancer
(T2c-T4) and pretreatment PSA levels <150 ng/mL.7 Patients were randomly assigned to short-term (ST) TAS for
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4 months starting at 2 months before RT or to the same
regimen with an additional 24 months of TAS (LT TAS).
Patients received conventional RT (external beam RT) to
the whole pelvis followed by a boost to the prostate to a
total dose of 67.5 Gy to 70 Gy. In Radiation Therapy Oncology Group (RTOG) study RTOG 9406, patients with T1T3 disease and PSA levels <70 ng/mL were eligible except
for patients with clinical stages T1b-c or T2a-b with a
GS of ≤5 and PSA levels ≤4 ng/mL.9 Patients received
3-dimensional conformal RT with a total dose level that
ranged from 68.4 Gy to 79.2 Gy. In RTOG 9413,6 patients had localized prostate cancer with an estimated
risk of lymph node involvement of >15% and PSA
levels ≤ 100 ng/mL. Patients were randomly assigned to
whole-pelvic RT (WPRT) + neoadjuvant and concurrent hormonal therapy (NHT), WPRT+adjuvant hormonal therapy
(AHT), prostate-only RT (PORT) + NHT, or PORT+AHT.
For the current meta-analysis, patients who were
enrolled into the 3 trials were categorized into 3 risk
groups using the following criteria: low risk (clinical
stages T1b-T2b, GS 2-6, and PSA <10 ng/mL); intermediate risk (clinical stages T1b-T2b and either GS 7 or PSA
10-20 ng/mL); high risk (clinical stages T2c-T4b, GS 8-10,
or PSA >20 ng/mL).10 The current study only analyzed patients in the high-risk group.

Measurement
The toxicity endpoints that were included were bowel
(ie, bowel, rectal, and other gastrointestinal), bladder (ie,
bladder and urinary), and clustered bowel and bladder toxicities (cluster definition is a patient with both late bowel
and late bladder toxicity of similar grades, within a time
frame of 2, 3, or 4 months of each other). These treatmentrelated late (>180 days from the start of RT) bowel and late
bladder toxicities were scored for severity on a scale from
1 to 5 by physicians using the RTOG Late Radiation Morbidity Scale (1, 2, 3, and 4 indicated minimal, moderate,
severe, and maximum severity, respectively; and 5 indicated death).11 Demographic and clinical variables were
collected at the time of enrollment or follow-up as appropriate through chart review.

Statistical analysis
Univariate and multivariable Fine-Gray regression
models12 were used to identify associations of treatment type
and sociodemographic variables for late bowel, late bladder,
and late clustered bowel and bladder toxicities. Patients who
died without experiencing an event were treated as a competing risk. For all analyses using the regression models,
eligible patients were randomly divided into 2 distinct
groups: Train and validation samples. All models were built
using the train sample and then evaluated/confirmed on the
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validation sample. Using this 2-step approach prevents
overfitting of the data and allows for the assessment of the
quality of the variable selection and evaluation of how reliable the predicted results are given these 2 samples. This
is necessary for the results to be generalized to the population of patients with high-risk prostate cancer.
All models were stratified by RTOG study. In the univariate and multivariable models, accrual year (continuous),
age (continuous), and Karnofsky Performance Status ([KPS];
70-80 vs. 90-100) were controlled for in the models.
Subsequently, the models were built by adding the following test variables (variables of interest to find associations)
in a stepwise fashion using the entry criterion of P < .05:
Treatment type, race (white vs nonwhite), marital status
(single vs married), number of people in household (lives
with others vs lives alone), family/friends who have cancer
(yes vs no), highest educational level (high school/graduate
equivalency degree [GED]/college/technical school vs <high
school/GED/college/technical school), employment status
(outside home/full-time/part-time vs other), household
income prior to illness (≥$25,000 vs <$25,000), and household income since illness (≥$25,000 vs <$25,000). Since
household income prior to and since illness are highly correlated, 2 separate models were built to test each of these
variables. Treatment type was categorized into the following 4 groups: Single modality of RT or hormone therapy
(HT) only; PORT+neoadjuvant HT (NHT) or adjuvant
HT (AHT)] = PORT+HT; WPRT+NHT or WPRT+ST
(≤4 months)–[NHT+concurrent HT (CCHT) + AHT]
or WPRT+ST–[CCHT+AHT] = WPRT+NHT/ST–HT;
and WPRT+LT (>4 months)–[NHT+CCHT+AHT] or
WPRT+LT–[CCHT+AHT]) = WPRT+LT–HT.

Results
Patients were accrued between 1992 and 2000. The total
eligible sample size from these 3 trials was 3837 patients.
There were 630 patients who were excluded from the
analyses for the following reasons: 100 patients were
missing pretreatment, sociodemographic, or follow-up data;
173 patients were node positive, had an orchiectomy in the
follow-up period, or were both node positive and had an
orchiectomy; and 357 patients had an undeterminable length
of total HT. The resulting sample size was 3207 patients.
These 3207 patients were categorized into 3 risk groups:
Low risk (clinical stages T1b-T2b, GS 2-6, and PSA
<10 ng/mL), intermediate risk (clinical stages T1b-T2b and
GS 7 or PSA 10-20 ng/mL), and high risk (clinical stages
T2c-T4b, GS 8-10, or PSA >20 ng/mL). The final subset
of patients that was used in this analysis was high risk and
included a total of 2432 patients.
Pretreatment sociodemographic data and treatment characteristics of the 2342 high-risk patients are shown in
Table 1. Of these patients, 39% were recruited between 1992
and 1994, 39% between 1994 and 1996, and 22% between

408

Advances in Radiation Oncology: July/September 2018

C. Xiao et al.

Table 1 Pretreatment sociodemographic and clinical characteristics of patients with high-risk prostate cancer (n = 2432)

Table 2 Late bowel and bladder toxicities (>180 days from start
of radiation therapy)

Number (%)

High-risk patients
(n = 2432)

Accrual year
1992-1994
1995-1997
1998-2000
Age (years)
≤70
>70
Race
White
African-American
Hispanic
Asian
Native American
Other
Marital status
Married/other live-in relationship
Single/divorced/separated/widowed
Prefer not to answer
Unknown
Highest education level
Never attended school
Grade 1-8 only
Some high school, did not graduate
High school/graduate equivalency degree
College/technical
Prefer not to answer
Unknown
Number of persons in household
Live alone
1 other
2-4 other
5 or more
Prefer not to answer
Unknown
Family/friends who have had cancer
Yes
No
Prefer not to answer
Unknown
Household income since becoming illa
<$8,000
$8,000-$14,999
$15,000-$24,999
$25,000-$34,999
$35,000-$49,999
≥$50,000
Prefer not to answer
Unknown
Karnofsky Performance Status score
70-80
90-100
Prescription type
Single modalityb
Prostate-only RT+HT
Whole pelvic RT+neoadjuvant HT/short-term HT
Whole pelvic RT+long-term HT

957 (39%)
948 (39%)
527 (22%)
1246 (51%)
1186 (49%)
1839 (76%)
480 (20%)
73 (3%)
13 (1%)
8 (<1%)
19 (1%)
1822 (75%)
569 (23%)
25 (1%)
16 (1%)
9 (<1%)
360 (15%)
380 (16%)
632 (26%)
878 (36%)
135 (6%)
38 (2%)
388 (16%)
1543 (63%)
402 (17%)
47 (2%)
35 (1%)
17 (1%)
1808 (74%)
540 (22%)
61 (3%)
23 (1%)
204 (8%)
411 (17%)
468 (19%)
202 (8%)
237 (10%)
270 (11%)
592 (24%)
48 (2%)
184 (8%)
2248 (92%)
131 (5%)
666 (27%)
832 (34%)
803 (33%)

HT, hormone therapy; RT, radiation therapy.
a

All income dollars for each accrual year were adjusted to Year 2000

dollars.
b

Twelve patients received HT alone.

Bowel

Bladder

Grade 0-1
Grade 2-5
Time to first grade 2-5 bowel
toxicity occurrence (months)
Mean
Median
Minimum-Maximum
Grade 0-2
Grade 3-5
Time to first grade 3-5 bowel
toxicity occurrence (months)
Mean
Median
Minimum-Maximum
Grade 0-1
Grade 2-5
Time to first grade 2-5 bladder
toxicity occurrence (months)
Mean
Median
Minimum-Maximum
Grade 0-2
Grade 3-5
Time to first grade 2-5 bladder
toxicity occurrence (months)
Mean
Median
Minimum-Maximum

2117 (87%)
315 (13%)

25.07
19.55
6.11-116.8
2379 (98%)
53 (2%)

27.60
21.22
9.17-116.8
2052 (84%)
380 (16%)

31.01
22.52
5.98-144.7
2353 (97%)
79 (3%)

35.73
27.96
6.14-117.9

1998 and 2000. The average age was 69.5 years (minimummaximum: 42-88 years) and most patients were Caucasian
(76%), married (75%), living with others (63%), and retired
(66%). Sixty-two percent of patients had at least a high
school education and 74% had family/friends that have had
cancer. Ninety-two percent of patients had a KPS of 90100 and 67% received WPRT+HT.
Table 2 contains the mean, median, minimum, and
maximum time for the grades ≥2 and ≥3 late bowel and
bladder toxicity occurrences, respectively. Thirteen percent
of patients experienced a late grade ≥2 bowel toxicity
(median time to occurrence: 20 months) and only 2%
experienced a late grade ≥3 bowel toxicity (median time
to occurrence: 21 months). Sixteen percent of patients
experienced a late grade ≥2 bladder toxicity (median time
to occurrence: 23 months) and only 3% experienced a late
grade ≥3 bladder toxicity (median time to occurrence:
28 months). Only 18, 24, and 29 patients (approximately
1%) experienced both late grade ≥2 bowel and bladder toxicities simultaneously at a 2-, 3-, or 4-month time frame,
respectively and only 2 patients (<1%) had both late grade
≥3 bowel and bladder toxicities at each time point (data
not shown).
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Table 3 (a) Multivariable Fine-Gray regression of grade ≥2 bowel toxicity for high-risk patients in the train sample (censored = 668;
events = 133; competing events = 415). (b) Multivariable Fine-Gray regression of grade ≥2 bowel toxicity for high-risk patients in the
validation sample (censored = 663; events = 182; competing events = 371)
A
Adjustment variables

Comparison

HRa

95% CI
LL

95% CI
UL

P-valueb

Accrual year
Age
KPS score

Continuous
Continuous
70-80
90-100
Single modality
Prostate-only RT+HT
Whole pelvic RT+neoadjuvant HT/short-term HT
Whole pelvic RT+long-term HT
White
Nonwhite

0.95
1.03
0.90
RL
0.20
0.36
1.09
RL
RL
0.60

0.80
0.99
0.45
—
0.06
0.18
0.75
—
—
0.37

1.13
1.05
1.79
—
0.69
0.73
1.60
—
—
0.96

.58
.058
.76
—
.011
.0046
.65
—
—
.035

Adjustment variables

Comparison

HRa

95% CI
LL

95% CI
UL

P-valueb

Accrual year
Age
KPS score

Continuous
Continuous
70-80
90-100
Single modality
Prostate-only RT+HT
Whole pelvic RT+neoadjuvant HT/short-term HT
Whole pelvic RT+long-term HT
White
Nonwhite

1.06
1.00
0.59
RL
0.60
0.43
0.85
RL
RL
0.75

0.93
0.98
0.29
—
0.24
0.23
0.60
—
—
0.51

1.20
1.02
1.20
—
1.46
0.80
1.22
—
—
1.08

.39
.82
.14
—
.26
.008
.39
—
—
.12

Prescription type

Race
B

Prescription type

Race

CI, confidence interval; HR, hazard ratio; HT, hormone therapy; KPS, Karnofsky Performance Status; LL, lower level; RL, reference level; RT, radiation therapy; UL, upper level.
a
HR <1 indicates that patients with the specific variable level’s characteristic have less risk of experiencing a late grade ≥2 bowel toxicity compared with the reference level after stratifying by Radiation Therapy Oncology Group study, controlling for accrual year, KPS, and age, and then
adjusting for other variables in the model.
b
P-values are from the Fine-Gray regression model.

The multivariable analysis showed consistent results
from both the train and validation samples. Patients who
received PORT+HT had a lower risk of experiencing a grade
≥2 bowel toxicity than patients who received WPRT+LT–
HT (Table 3(a); hazard ratio [HR]: 0.36; 95% confidence
interval [CI], 0.18-0.73; P = .0046 and Table 3(b); HR: 0.43;
95% CI, 0.23-0.80; P = .008). The result from the train
sample of patients who were treated with a single modality
and had a lower risk of experiencing grade ≥2 bowel toxicity than WPRT+LT–HT patients (Table 3(a); HR: 0.20;
95% CI, 0.06-0.69; P = .011) was not confirmed in the validation sample (Table 3(b); HR: 0.60; 95% CI, 0.24-1.46;
P = .26).
There appeared to be a protective effect against grade
≥2 bladder toxicity for both patients prescribed single modality (Table 4(a); HR: 0.24; 95% CI, 0.08-0.72; P = .011)
and PORT+HT (Table 4(a); HR: 0.53; 95% CI, 0.310.90; P = .018) compared with patients who received
WPRT+LT–HT in the train sample but this was not

confirmed with the validation sample (Table 4 (b); HR: 1.05;
95% CI, 0.51-2.18; P = .89 for single modality and HR:
0.77; 95% CI, 0.48-1.23; P = .28 for PORT+HT).
Both the train and validation samples also demonstrated that patients who received WPRT+NHT/ST–HT
showed no difference in grade ≥2 bowel or bladder toxicity risk than patients who received WPRT+LT–HT (Tables 3
and 4). In other words, as long as patients received WPRT,
there was no difference of grade ≥2 bowel or bladder toxicity no matter if they received LT or ST HT+AHT or NHT,
or both.
Since there are a small number of late grade ≥3 bowel
toxicity events, only univariate analyses were performed.
Patients who were prescribed single-modality PORT+HT
seem to have a lower risk of grade ≥3 bowel toxicity than
the reference group of patients who were treated with
WPRT+LT–HT (HR: 0.11; 95% CI, 0.01-0.89; P = .039)
but this was not confirmed in the validation sample
(HR: 0.22; 95% CI, 0.05-1.10; P = .065). Likewise,
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Table 4 (a) Multivariable Fine-Gray regression of grade ≥2 bladder toxicity for high-risk patients in the train sample (censored = 651;
events = 177; competing events = 388). (b) Multivariable Fine-Gray regression of grade ≥2 bladder toxicity for high-risk patients in the
validation sample (censored = 630; events = 203; competing events = 383)
A
Adjustment variables

Comparison

HRa

95% CI
LL

95% CI
UL

P-valueb

Accrual year
Age
KPS score

Continuous
Continuous
70-80
90-100
Single modality
Prostate-only RT+HT
Whole pelvic RT+neoadjuvant HT/short-term HT
Whole pelvic RT+long-term HT

1.01
1.00
1.14
RL
0.24
0.53
0.84
RL

0.88
0.98
0.66
—
0.08
0.31
0.59
—

1.16
1.02
1.95
—
0.72
0.90
1.19
—

.91
.94
.64
—
.011
.018
.32
—

Adjustment variables

Comparison

HRa

95% CI
LL

95% CI
UL

P-valueb

Accrual year
Age
KPS score

Continuous
Continuous
70-80
90-100
Single modality
Prostate-only RT+HT
Whole pelvic RT+neoadjuvant HT/short-term HT
Whole pelvic RT+long-term HT

1.10
1.00
1.13
RL
1.05
0.77
0.71
RL

0.97
0.98
0.67
—
0.51
0.48
0.49
—

1.24
1.02
1.90
—
2.18
1.23
1.02
—

.13
.86
.65
—
.89
.28
.063
—

Prescription type

B

Prescription type

CI, confidence interval; HR, hazard ratio; HT, hormone therapy; KPS, Karnofsky Performance Status; LL, lower level; RL, reference level; RT, radiation therapy; UL, upper level.
a
HR <1 indicates that patients with the specific variable level’s characteristic have less risk of experiencing a late grade ≥2 bladder toxicity
compared with the reference level after stratifying by Radiation Therapy Oncology Group study, controlling for accrual year, KPS, and age, and
then adjusting for other variables in the model.
b
P-values are from the Fine-Gray regression model.

patients who earn <$25,000 (including those who preferred not to answer or with missing answers) prior to
illness appear to have a higher risk of grade ≥3 bowel
toxicity (HR: 8.93; 95% CI, 1.17-68.05; P = .035) but this
was also not confirmed in the validation sample (HR: 1.04;
95% CI, 0.50-2.13; P = .93). A similar finding related to
income was indicated in grade ≥3 bladder toxicity. Patients who earn <$25,000 since their illness appear to
have a higher risk of grade ≥3 bowel toxicity (HR: 4.58;
95% CI, 1.48-14.23; P = .0085) but again, this was not
confirmed in the validation sample (HR: 1.32; 95% CI,
0.66-2.64; P = .43).

Discussion
The major finding from this meta-analysis of 2432 patients with high-risk prostate cancer enrolled into 3 large
randomized clinical trials is that the treatment types may
play a significant role in predicting whether patients experience late bowel and bladder toxicities. All statistical
models in this meta-analysis were stratified by the 3 studies

and major confounders such as age and KPS were controlled. The analyses indicate that high-risk patients who
receive WPRT plus >4 months of HT are 3 times more likely
to have a grade ≥2 bowel toxicity than those who receive
PORT+HT but the differences for grade ≥2 bladder toxicity between the 2 groups cannot be confirmed in our data.
The significant finding for bowel toxicities is consistent with
the RTOG 9413, which showed that late grade ≥2 gastrointestinal toxicities were higher in the WPRT arm than in
the PORT arm.13
Additionally, this meta-analysis suggests that as long as
patients receive WPRT, their chances of experiencing grade
≥2 bowel and bladder toxicities are the same no matter
whether they receive LT or ST HT+AHT or NHT, or both.
This finding indicates that the bowel and bladder toxicities are more likely due to RT than to androgen suppression
therapy. Although WPRT in our meta-analysis was linked
to more grade ≥2 bowel toxicity, WPRT does show a
progression-free survival benefit.13 Two current phase 3 randomized clinical trials (RTOG 0924 in the United States14
and PEACE2 in Europe15) will help clarify the potential
beneficial effects of WPRT in the setting of higher doses
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of RT and contemporary RT delivery techniques for highrisk patients.
The analyses also suggest that patients experience bowel
toxicities earlier than bladder toxicities (average of 6 months
earlier for grade ≥2 and 8 months earlier for grade ≥3).
Moreover, the majority of patients appear to not experience both bowel and bladder toxicities simultaneously. Only
approximately 1% of patients experienced both late grade
≥2 bowel and bladder toxicities simultaneously and <1%
of patients had both late grade ≥3 bowel and bladder toxicities. The explanation for these findings is unclear and
the results need to be compared with even more current RT
techniques such as intensity modulated RT. However, these
descriptive data provide evidence for clinicians’ expectation for toxicities development and may guide toxicity
management.
Other risk factors such as accrual year over the time
period from 1992 to 2000 were hypothesized to play a significant role in predicting whether patients experience later
bowel and bladder toxicities because radiation planning and
technology improved over that period of time. However,
the results did not indicate that the accrual year or change
of RT from conventional RT7 to 3-dimensional conformal
RT9 was associated with a decreased toxicity profile. Additionally, although lower household income prior to
illness (<$25,000/prefer not to answer/missing) or since
illness appeared to be associated with higher grade ≥3
bladder or bowel toxicities, this finding cannot be confirmed in the validation sample.

Limitations
Although this meta-analysis is based on data from 3 large
randomized clinical trials, there are limitations. First, the
study and findings are not from a prospective study design
so the study itself is not powered and the interpretation of
the findings should be done with caution. Second, the sample
size for patients with grade ≥3 bowel and bladder toxicities is relative small, which could bias the results. In addition,
data with regard to comorbidities were not available to
analyze for this cohort but we did have KPS in the model.
Lastly, the data may not reflect current RT planning and
technology used. However, the findings still provide evidence in support of the different impact that RT types have
on late bowel and bladder toxicities.

Conclusions
The findings of this meta-analysis show that patients with
high-risk prostate cancer who receive WPRT plus >4 months
of HT are more likely to have a grade ≥2 bowel toxicity
than those who receive PORT+HT but the differences for
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grade ≥2 bladder toxicity between the 2 groups cannot be
confirmed in this data. The findings in this report also
suggest that as long as patients receive WPRT, their chances
of experiencing grade ≥2 bowel and bladder toxicities are
the same no matter whether they receive LT or ST HT+AHT
or NHT, or both. Additionally, very few patients experience both bladder and bowel toxicities. These findings may
provide evidence for toxicity management in clinical settings. Future studies on the basis of more advanced radiation
technologies and patient-reported outcomes are warranted to confirm these findings.
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